Advertisement
Screener

Perrigo Company plc (PRGO) Graph

PRGO Revenue Flow

Filed revenue amounts for 2026-03-29 to 2026-06-27. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

  • 2026-06-27: Revenue $1.02B; Revenue including tax (m); Cost of revenue $708.90M; Research and development $23.70M.
  • 2026-03-28: Revenue $969.20M; Revenue including tax (m); Cost of revenue $643.70M; Research and development $24.60M.
  • 2025-12-31: Revenue $1.11B*; Revenue including tax (m); Cost of revenue $747.40M*; Research and development $21.80M*.
  • 2025-09-27: Revenue $1.04B; Revenue including tax (m); Cost of revenue $666.20M; Research and development $24.90M.

Consolidation item

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

PRGO revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.MaterialReconciling Items$118.60MOperating Segments$904.10MRevenue$1.02BCost of revenue$708.90MGross profit$313.90MOperating expenses$290.50MOperating income$23.50MOther income, net$120.50MResearch & development$23.70MPre-tax income$105.40MIncome tax$16.90MNet income$74.50M

Geography

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

PRGO revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Europe$371.70MOther GeographicalAreas$24.70MIE$7.70MUS$626.40MRevenue$1.02BCost of revenue$708.90MGross profit$313.90MOperating expenses$290.50MOperating income$23.50MOther income, net$120.50MResearch & development$23.70MPre-tax income$105.40MIncome tax$16.90MNet income$74.50M

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueRevenue including taxCost of revenueResearch and developmentOperating expensesIncome taxNet income
2026-06-27$1.02B(m)$708.90M$23.70M$290.50M$16.90M$74.50M
2026-03-28$969.20M(m)$643.70M$24.60M$697.80M-$18.70M-$398.60M
2025-12-31$1.11B*(m)$747.40M*$21.80M*$1.65B*$82.90M*-$1.42B*
2025-09-27$1.04B(m)$666.20M$24.90M$304.50M$9.70M$7.50M
2025-06-28$1.06B(m)$693.40M$22.00M$317.50M$3.70M-$8.40M
2025-03-29$1.04B(m)$651.60M$26.70M$345.40M$8.20M-$6.40M
2024-09-28$1.09B(m)$683.10M$26.00M$324.00M$39.40M-$21.00M
2024-06-29$1.07B(m)$670.80M$29.40M$421.20M$31.70M-$108.40M
2024-03-30$1.08B(m)$724.40M$29.00M$412.90M-$102.70M$2.00M
2023-09-30$1.12B(m)$712.60M$29.60M$349.10M$3.80M$14.20M
2023-07-01$1.19B(m)$765.10M$32.20M$371.20M$13.60M$8.40M
2023-04-01$1.18B(m)$767.90M$31.10M$365.30M$5.40M-$3.00M
2022-10-01$1.10B(m)$737.30M$29.80M$329.80M$48.60M-$49.40M
2022-07-02$1.12B(m)$749.60M$31.50M$379.00M-$43.40M-$65.10M
2022-04-02$1.07B(m)$736.70M$29.30M$316.10M-$11.70M-$2.40M
2021-10-02$1.04B(m)$706.30M$27.60M-$101.90M$442.80M-$58.90M
2021-07-03$981.10M(m)$632.10M$33.00M$474.90M-$45.20M-$57.70M
2021-04-03$1.01B(m)$641.60M$31.10M$317.00M$14.20M$38.10M
2020-12-31$1.29B(m)(m)(m)(m)(m)-$175.00M
2020-09-30$1.21B(m)(m)(m)(m)(m)-$154.60M
2020-09-26$1.00B(m)$633.30M$30.40M$291.20M$22.00M-$154.60M
2020-06-30$1.22B(m)(m)(m)(m)(m)$60.60M
2020-06-27$948.80M(m)$601.60M$30.40M$284.50M$3.10M$60.60M
2020-03-31$1.34B(m)(m)(m)(m)(m)$106.40M
2020-03-28$1.08B(m)$689.60M$27.90M$307.30M-$200.00K$106.40M
2019-12-31$1.32B(m)(m)(m)(m)(m)-$19.00M
2019-09-28$1.19B(m)$778.30M$44.00M$358.40M$5.10M$92.20M
2019-06-29$1.15B(m)$718.20M$43.90M$375.80M$18.00M$9.00M
2019-03-30$1.17B(m)$725.70M$40.20M$346.50M$17.00M$63.90M
2018-12-31$1.20B(m)(m)(m)(m)(m)$81.50M
2018-09-29$1.13B(m)$708.30M$43.70M$546.80M-$11.50M-$67.50M
2018-06-30$1.19B$77.10M$715.40M$91.90M$376.30M$19.10M$36.20M
2018-03-31$1.22B(m)$724.30M$38.40M$336.40M$29.70M$80.80M
2017-12-31$1.28B(m)(m)(m)(m)(m)$73.10M
2017-09-30$1.23B(m)$733.50M$38.40M$335.40M$84.20M$44.50M
2017-07-01$1.24B(m)$733.30M$42.60M$355.80M-$6.70M-$69.60M
2017-04-01$1.19B(m)$729.60M$39.80M$335.90M$24.20M$71.60M
2016-12-31$1.33B(m)(m)(m)(m)(m)-$1.36B
2016-10-01$1.26B(m)$777.10M$50.20M$1.95B-$311.80M-$1.59B
2016-07-02$1.34B(m)$794.00M$47.00M$361.70M-$277.90M-$534.30M
2016-04-02$1.35B(m)$814.20M$45.30M$764.70M$39.10M-$529.20M
2015-12-31$1.36B(m)(m)(m)(m)(m)-$218.40M
2015-09-26$1.27B(m)$737.90M$41.60M$359.90M$33.90M$260.90M
2015-06-27$1.42B(m)$814.20M$62.60M$408.70M$82.70M-$22.20M
2015-03-28$967.20M(m)$597.80M$35.40M$179.00M$12.00M-$22.20M
2014-12-27$985.10M(m)$687.90M$53.20M$199.40M$14.50M$151.10M
2014-09-27$859.60M(m)$629.70M$36.60M$184.60M$12.30M$29.40M
2014-06-28$1.14B(m)(m)(m)(m)(m)$131.70M
2014-03-29$1.00B(m)$689.20M$44.70M$211.70M$14.60M$48.10M
2013-12-28$979.00M(m)$618.30M$37.50M$274.10M-$27.00M-$86.00M
2013-09-28$933.40M(m)$577.10M$32.30M$176.60M$45.90M$111.40M
2013-06-29$967.20M(m)(m)(m)(m)(m)$118.50M
2013-03-30$919.80M(m)$588.40M$28.50M$152.80M$48.20M$111.90M
2012-12-29$883.00M(m)$575.80M$28.30M$143.30M$39.50M$106.00M
2012-09-29$769.80M(m)(m)(m)(m)(m)$105.60M

Revenue and expense 6 month

Period endRevenueRevenue including taxCost of revenueResearch and developmentOperating expensesIncome taxNet income
2026-06-27$1.99B(m)$1.35B$48.40M$988.30M-$1.80M-$324.10M
2025-06-28$2.10B(m)$1.34B$48.70M$662.90M$11.90M-$14.80M
2024-06-29$2.15B(m)$1.40B$58.40M$834.10M-$71.00M-$106.40M
2023-07-01$2.37B(m)$1.53B$63.30M$736.50M$19.00M$5.40M
2022-07-02$2.20B(m)$1.49B$60.80M$695.10M-$55.10M-$67.60M
2021-07-03$1.99B(m)$1.27B$64.10M$792.00M-$31.00M-$19.60M
2020-06-27$2.03B(m)$1.29B$58.30M$591.80M$2.80M$167.00M
2019-06-29$2.32B(m)$1.44B$84.00M$722.30M$35.00M$72.90M
2018-06-30$2.40B$146.50M$1.44B$130.30M$712.80M$48.80M$117.00M
2017-07-01$2.43B(m)$1.46B$82.30M$691.60M$17.60M$2.00M
2016-07-02$2.69B(m)$1.61B$92.20M$1.13B-$238.90M-$1.06B
2015-12-31$2.63B(m)$1.55B$88.20M$1.01B-$33.60M$42.50M
2015-06-27$2.38B(m)$1.41B$98.00M$587.70M$94.70M-$44.50M
2014-12-27$1.84B(m)$1.17B$89.80M$384.10M$29.40M$180.60M
2013-12-28$4.06B(m)$1.20B$69.80M$450.80M$18.90M$25.30M
2012-12-29$1.65B(m)$1.06B$55.70M$272.00M$74.70M$211.50M

Revenue and expense 9 month

Period endRevenueCost of revenueResearch and developmentOperating expensesIncome taxNet income
2025-09-27$3.14B$2.01B$73.60M$967.40M$21.50M-$7.30M
2024-09-28$3.24B$2.08B$84.40M$1.16B-$31.50M-$127.30M
2023-09-30$3.50B$2.25B$92.90M$1.09B$22.70M$19.60M
2022-10-01$3.30B$2.22B$90.50M$1.02B-$6.60M-$116.90M
2021-10-02$3.03B$1.98B$91.70M$690.10M$411.80M-$78.50M
2020-09-26$3.04B$1.92B$88.70M$882.90M$24.90M$12.40M
2019-09-28$3.51B$2.22B$128.00M$1.08B$40.10M$165.10M
2018-09-29$3.54B$2.15B$174.00M$1.26B$37.30M$49.60M
2017-09-30$3.66B$2.20B$120.80M$1.03B$101.80M$46.40M
2016-10-01$3.95B$2.39B$142.50M$3.08B-$550.70M-$2.65B
2015-09-26$3.66B$2.15B$139.70M$947.60M$128.60M$216.40M
2015-03-28$3.07B$1.99B$125.20M$563.60M$19.10M$71.50M
2014-03-29$2.92B$1.88B$114.50M$662.40M$33.50M$73.40M
2013-03-30$2.57B$1.65B$84.20M$424.80M$122.80M$323.50M

Revenue and expense 12 month

Period endRevenueCost of revenueResearch and developmentOperating expensesIncome taxNet income
2025-12-31$4.25B$2.76B$95.40M$2.62B$104.40M-$1.43B
2024-12-31$4.37B$2.83B$112.20M$1.43B$80.00M-$171.80M
2023-12-31$4.66B$2.98B$122.50M$1.53B-$3.90M-$12.70M
2022-12-31$4.45B$3.00B$123.10M$1.38B-$8.20M-$140.60M
2021-12-31$4.14B$2.72B$122.00M$1.01B$389.60M-$68.90M
2020-12-31$4.09B$2.59B$121.70M$1.23B-$38.30M-$162.60M
2019-12-31$3.87B$2.44B$119.20M$1.26B-$10.70M$146.10M
2018-12-31$4.73B$2.90B$218.60M$1.59B$159.60M$131.00M
2017-12-31$4.95B$2.97B$167.70M$1.38B$160.50M$119.60M
2016-12-31$5.28B$3.23B$184.00M$4.05B-$835.50M-$4.01B
2015-06-27$4.23B$2.58B$187.80M$971.70M$124.20M$136.10M
2014-06-28$3.91B$2.46B$152.50M$880.70M$70.80M$232.80M
2013-06-29(m)$2.26B$115.20M$600.90M$165.80M$441.90M
2012-06-30$3.17B$2.08B$105.80M(m)$119.00M$401.60M

Similar stocks

Stock NameCountryMarket CapPE Ratio
NEKTAR THERAPEUTICS (NKTR)United States$2.026B-9.05
Generate Biomedicines, Inc. (GENB)United States$2.052B
UroGen Pharma Ltd. (URGN)$2.015B-18.42
Nuvation Bio Inc. (NUVB)United States$2.007B-13.12
Biohaven Ltd. (BHVN)United States$1.990B-3.83
Trevi Therapeutics, Inc. (TRVI)United States$2.091B-51.93
PALVELLA THERAPEUTICS, INC. (PVLA)United States$2.105B-35.55
Braveheart Bio, Inc. (BRVE)United States$2.106B
Bausch Health Companies Inc. (BHC)$2.113B-1.68
AGIOS PHARMACEUTICALS, INC. (AGIO)United States$1.962B-5.38